Journal
FRONTIERS IN IMMUNOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2019.00181
Keywords
tolerance; dendritic cells; regulatory T cells; autoimmunity; transplantation; cell therapy; clinic; immunomonitoring
Categories
Funding
- COST (European Cooperation in Science and Technology) [BM1305]
- COST
- EU Framework Programme Horizon 2020
- ONE Study, EU FP7 Funding Program
- BIO-DrIM, EU FP7 Funding Program
- ReSToRe, EU H2020 Funding Program
- National Center for Research and Development, PL [STRATEGMED1/233368/1/NCBR/2014]
- integrated in the Plan Nacional de I+D+I [PI14/01175, PI16/01737, PI17/01521]
- ISCIII-Subdireccion General de Evaluacion
- Fondo Europeo de Desarrollo Regional (FEDER)
- Institute for the Promotion of Innovation by Science and Technology (IWT-TMB) in Flanders (Belgium) [140191]
Ask authors/readers for more resources
Clinical studies with cellular therapies using tolerance-inducing cells, such as tolerogenic antigen-presenting cells (tolAPC) and regulatory T cells (Treg) for the prevention of transplant rejection and the treatment of autoimmune diseases have been expanding the last decade. In this perspective, we will summarize the current perspectives of the clinical application of both tolAPC and Treg, and will address future directions and the importance of immunomonitoring in clinical studies that will result in progress in the field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
